118 related articles for article (PubMed ID: 3611093)
1. Characterization of an antibody-urokinase conjugate. A plasminogen activator targeted to fibrin.
Bode C; Runge MS; Newell JB; Matsueda GR; Haber E
J Biol Chem; 1987 Aug; 262(22):10819-23. PubMed ID: 3611093
[TBL] [Abstract][Full Text] [Related]
2. Thrombolysis by a fibrin-specific antibody Fab'-urokinase conjugate.
Bode C; Runge MS; Newell JB; Matsueda GR; Haber E
J Mol Cell Cardiol; 1987 Apr; 19(4):335-41. PubMed ID: 3612817
[TBL] [Abstract][Full Text] [Related]
3. Conjugation to antifibrin Fab' enhances fibrinolytic potency of single-chain urokinase plasminogen activator.
Bode C; Runge MS; Schönermark S; Eberle T; Newell JB; Kübler W; Haber E
Circulation; 1990 Jun; 81(6):1974-80. PubMed ID: 2111744
[TBL] [Abstract][Full Text] [Related]
4. Conjugation to an antifibrin monoclonal antibody enhances the fibrinolytic potency of tissue plasminogen activator in vitro.
Runge MS; Bode C; Matsueda GR; Haber E
Biochemistry; 1988 Feb; 27(4):1153-7. PubMed ID: 3130094
[TBL] [Abstract][Full Text] [Related]
5. A bispecific antibody enhances the fibrinolytic potency of single-chain urokinase.
Charpie JR; Runge MS; Matsueda GR; Haber E
Biochemistry; 1990 Jul; 29(27):6374-8. PubMed ID: 1698452
[TBL] [Abstract][Full Text] [Related]
6. Platelet-targeted fibrinolysis enhances clot lysis and inhibits platelet aggregation.
Bode C; Meinhardt G; Runge MS; Freitag M; Nordt T; Arens M; Newell JB; Kübler W; Haber E
Circulation; 1991 Aug; 84(2):805-13. PubMed ID: 1860223
[TBL] [Abstract][Full Text] [Related]
7. Biochemical properties of conjugates of urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin.
Dewerchin M; Lijnen HR; Van Hoef B; De Cock F; Collen D
Eur J Biochem; 1989 Oct; 185(1):141-9. PubMed ID: 2530085
[TBL] [Abstract][Full Text] [Related]
8. Antibody-directed fibrinolysis: a bispecific (Fab')2 that binds to fibrin and tissue plasminogen activator.
Runge MS; Bode C; Savard CE; Matsueda GR; Haber E
Bioconjug Chem; 1990; 1(4):274-7. PubMed ID: 2129015
[TBL] [Abstract][Full Text] [Related]
9. Antibody-directed urokinase: a specific fibrinolytic agent.
Bode C; Matsueda GR; Hui KY; Haber E
Science; 1985 Aug; 229(4715):765-7. PubMed ID: 4023710
[TBL] [Abstract][Full Text] [Related]
10. Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis model.
Collen D; Dewerchin M; Rapold HJ; Lijnen HR; Stassen JM
Circulation; 1990 Nov; 82(5):1744-53. PubMed ID: 2121385
[TBL] [Abstract][Full Text] [Related]
11. Effect of fibrin-targeting on clot lysis with urokinase-type plasminogen activator.
Lijnen HR; Dewerchin M; De Cock F; Collen D
Thromb Res; 1990 Feb; 57(3):333-42. PubMed ID: 2107593
[TBL] [Abstract][Full Text] [Related]
12. Hybrid molecules: insights into plasminogen activator function.
Runge MS; Bode C; Haber E; Quertermous T
Mol Biol Med; 1991 Apr; 8(2):245-55. PubMed ID: 1806766
[TBL] [Abstract][Full Text] [Related]
13. A bispecific antifibrin-antiplatelet urokinase conjugate (BAAUC) induces enhanced clot lysis and inhibits platelet aggregation.
Ruef J; Nordt TK; Peter K; Runge MS; Kübler W; Bode C
Thromb Haemost; 1999 Jul; 82(1):109-14. PubMed ID: 10456463
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a recombinant fusion protein of the finger domain of tissue-type plasminogen activator with a truncated single chain urokinase-type plasminogen activator.
Gheysen D; Lijnen HR; Piérard L; de Foresta F; Demarsin E; Jacobs P; De Wilde M; Bollen A; Collen D
J Biol Chem; 1987 Aug; 262(24):11779-84. PubMed ID: 3114253
[TBL] [Abstract][Full Text] [Related]
15. Antibody-enhanced thrombolysis: targeting of tissue plasminogen activator in vivo.
Runge MS; Bode C; Matsueda GR; Haber E
Proc Natl Acad Sci U S A; 1987 Nov; 84(21):7659-62. PubMed ID: 3118374
[TBL] [Abstract][Full Text] [Related]
16. Biochemical characterization of single-chain chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody and single-chain urokinase.
Holvoet P; Laroche Y; Lijnen HR; Van Hoef B; Brouwers E; De Cock F; Lauwereys M; Gansemans Y; Collen D
Eur J Biochem; 1992 Dec; 210(3):945-52. PubMed ID: 1483477
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a chimeric plasminogen activator consisting of a single-chain Fv fragment derived from a fibrin fragment D-dimer-specific antibody and a truncated single-chain urokinase.
Holvoet P; Laroche Y; Lijnen HR; Van Cauwenberge R; Demarsin E; Brouwers E; Matthyssens G; Collen D
J Biol Chem; 1991 Oct; 266(29):19717-24. PubMed ID: 1918077
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a recombinant chimeric plasminogen activator composed of a fibrin fragment-D-dimer-specific humanized monoclonal antibody and a truncated single-chain urokinase.
Vandamme AM; Dewerchin M; Lijnen HR; Bernar H; Bulens F; Nelles L; Collen D
Eur J Biochem; 1992 Apr; 205(1):139-46. PubMed ID: 1313361
[TBL] [Abstract][Full Text] [Related]
19. Effect of a synthetic carboxy-terminal peptide of alpha(2)-antiplasmin on urokinase-induced fibrinolysis.
Lee KN; Jackson KW; McKee PA
Thromb Res; 2002 Feb; 105(3):263-70. PubMed ID: 11927133
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a recombinant chimeric plasminogen activator with enhanced fibrin binding.
Jiao J; Yu M; Ru B
Biochim Biophys Acta; 2001 Apr; 1546(2):399-405. PubMed ID: 11295444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
